Mike C. Diem
Director/Board Member chez Trinity Biosystems, Inc.
Fortune : 1 M $ au 31/03/2024
Profil
Mike C.
Diem is currently a Director at Protez Pharmaceuticals, Inc., Trinity Biosystems, Inc., GlaxoSmithKline North Carolina, The Boys & Girls Clubs of Philadelphia, UPMC Enterprises, and Pfizer Venture Investments LLC.
He has also held positions as a Director at Adheron Therapeutics, Inc., NuPathe, Inc., CalciMedica, Inc. (US), Aileron Therapeutics, Inc., and Venatorx Pharmaceuticals, Inc. Additionally, he served as the Senior VP-Business & Corporate Development at Amicus Therapeutics, Inc. from 2017 to 2020.
He was also a Principal at GSK Equity Investments Ltd.
from 2005 to 2009 and the Head-Strategy & Development at AstraZeneca, Inc. He has an MBA from Case Western Reserve University, an undergraduate degree from Rutgers State University of New Jersey, and a doctorate from Robert Wood Johnson Medical School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 01/11/2023 | 253 533 ( 0,31% ) | 1 M $ | 31/03/2024 |
Postes actifs de Mike C. Diem
| Sociétés | Poste | Début |
|---|---|---|
Trinity Biosystems, Inc.
 Trinity Biosystems, Inc. Pharmaceuticals: MajorHealth Technology Trinity Biosystems, Inc. develops and formulates orally delivered bio-therapeutic macromolecules. It offers TriPex system, an approach to macromolecule delivery that works cooperatively with the natural physiology of the body. The system utilizes a specific and natural biological transport mechanism: a receptor-mediated transcellular transport pathway that allows passage through the mucosal epithelium and delivery of the therapeutic payload into the blood. The company was founded by Randall J. Mrsny on July 19, 2002 and is headquartered in Menlo Park, CA. | Director/Board Member | 18/09/2009 |
Protez Pharmaceuticals, Inc.
 Protez Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Protez Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. It develops antibiotics for infections & provides research service on intravenous & oral small molecule antibiotics to chronic and recurrent infections. The company was founded by Klaus Esser, Luigi Xerri & Christopher M. Cashman in 2003 and is headquartered in Malvern, PA. | Director/Board Member | 23/02/2011 |
GlaxoSmithKline North Carolina
 GlaxoSmithKline North Carolina Pharmaceuticals: OtherHealth Technology Part of GSK Plc, GlaxoSmithKline North Carolina is a private company that develops, manufactures, and markets vaccines and other pharmaceuticals. The company is based in Durham, NC. | Corporate Officer/Principal | 21/06/2011 |
| The Boys & Girls Clubs of Philadelphia | Director/Board Member | - |
UPMC Enterprises
 UPMC Enterprises Investment ManagersFinance UPMC Enterprises (UPMC Enterprises) is a venture capital subsidiary of University of Pittsburgh Medical Center founded in 2014. The firm is headquartered in Pittsburgh, Pennsylvania. | Consultant / Advisor | - |
Pfizer Venture Investments LLC
 Pfizer Venture Investments LLC Investment ManagersFinance Pfizer Ventures Investments LLC (Pfizer Ventures Investments) is a venture capital subsidiary of Pfizer Inc. founded in 2001. The firm is headquartered in New York. | Private Equity Investor | 01/02/2024 |
Anciens postes connus de Mike C. Diem
| Sociétés | Poste | Fin |
|---|---|---|
| CENTURY THERAPEUTICS, INC. | Director of Finance/CFO | 02/02/2024 |
Venatorx Pharmaceuticals, Inc.
 Venatorx Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Venatorx Pharmaceuticals, Inc. develops novel anti-infective agents to address the threat of antibiotic resistance. It offers antibiotic resistant bacteria and Carbapenem-resistant Enterobacteriaceae a family of gram-negative bacteria that are resistant to all known ?-lactam antibiotics, including penicillins, cephalosporins, monobactams, and carbapenems. The company was founded by Christopher J. Burns, Luigi Xerri, and Daniel Pevear in 2010 and is headquartered in Malvern, PA. | Director/Board Member | 07/03/2023 |
| AMICUS THERAPEUTICS, INC. | Corporate Officer/Principal | 01/09/2020 |
| ░░░░ ░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░ ░░░░░░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Formation de Mike C. Diem
| Case Western Reserve University | Masters Business Admin |
| Rutgers State University of New Jersey | Undergraduate Degree |
| Robert Wood Johnson Medical School | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| AMICUS THERAPEUTICS, INC. | Health Technology |
| AILERON THERAPEUTICS, INC. | Health Technology |
| CENTURY THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 15 |
|---|---|
Adheron Therapeutics, Inc.
 Adheron Therapeutics, Inc. BiotechnologyHealth Technology Adheron Therapeutics, Inc. discovers and develops therapeutic drugs. The firm offers Cadherin-11 antagonists for the treatment of rheumatoid arthritis and fibrotic diseases including pulmonary fibrosis and skin fibrosis. The company was founded by David Lee, Michael B. Brenner, and David L. Castaldi in 2006 and is headquartered in Berkeley, CA. | Health Technology |
NuPathe, Inc.
 NuPathe, Inc. Medical SpecialtiesHealth Technology NuPathe, Inc. develops pharmaceutical and therapeutic products. It focuses on the development and commercialization of branded therapeutics for diseases of central nervous system, including neurological and psychiatric disorders. The company was founded by Terri B. Sebree and Jane Holmes Hollingsworth in 2005 and is headquartered in Malvern, PA. | Health Technology |
CalciMedica, Inc. (US)
 CalciMedica, Inc. (US) BiotechnologyHealth Technology CalciMedica, Inc. is a holding company, which engages in drug development. It discovers and develops novel small molecule drugs for the treatment of inflammatory and autoimmune disorders and organ transplant rejection. The company was founded by Gonul Velicelebi, Kenneth Stauderman, Anjana Rao, Patrick Hogan, Stefan Feske, Michael Harpold, Tom Reed, and Jack Roos in December 2006 and is headquartered in La Jolla, CA. | Health Technology |
Venatorx Pharmaceuticals, Inc.
Venatorx Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Venatorx Pharmaceuticals, Inc. develops novel anti-infective agents to address the threat of antibiotic resistance. It offers antibiotic resistant bacteria and Carbapenem-resistant Enterobacteriaceae a family of gram-negative bacteria that are resistant to all known ?-lactam antibiotics, including penicillins, cephalosporins, monobactams, and carbapenems. The company was founded by Christopher J. Burns, Luigi Xerri, and Daniel Pevear in 2010 and is headquartered in Malvern, PA. | Commercial Services |
GSK Equity Investments Ltd.
 GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity Investment Ltd (GSK Equity) is a venture capital firm a subsidiary of GlaxoSmithKline Plc founded in 1985. The firm is headquartered in Reedwood City, California. | Finance |
Protez Pharmaceuticals, Inc.
Protez Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Protez Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. It develops antibiotics for infections & provides research service on intravenous & oral small molecule antibiotics to chronic and recurrent infections. The company was founded by Klaus Esser, Luigi Xerri & Christopher M. Cashman in 2003 and is headquartered in Malvern, PA. | Health Technology |
Pfizer Venture Investments LLC
Pfizer Venture Investments LLC Investment ManagersFinance Pfizer Ventures Investments LLC (Pfizer Ventures Investments) is a venture capital subsidiary of Pfizer Inc. founded in 2001. The firm is headquartered in New York. | Finance |
Aevi Genomic Medicine, Inc.
 Aevi Genomic Medicine, Inc. Pharmaceuticals: MajorHealth Technology Aevi Genomic Medicine, Inc. is a clinical stage biopharmaceutical company, which engaged in the discovery of treatments for rare and orphan diseases. Its research and development efforts leverage an internal genomics platform and an ongoing collaboration with the Center for Applied Genomics (CAG) at The Children's Hospital of Philadelphia (CHOP). The company was founded by Andrew Leonard Pearlman on January 27, 2000 and is headquartered in Wayne, PA. | Health Technology |
Trinity Biosystems, Inc.
Trinity Biosystems, Inc. Pharmaceuticals: MajorHealth Technology Trinity Biosystems, Inc. develops and formulates orally delivered bio-therapeutic macromolecules. It offers TriPex system, an approach to macromolecule delivery that works cooperatively with the natural physiology of the body. The system utilizes a specific and natural biological transport mechanism: a receptor-mediated transcellular transport pathway that allows passage through the mucosal epithelium and delivery of the therapeutic payload into the blood. The company was founded by Randall J. Mrsny on July 19, 2002 and is headquartered in Menlo Park, CA. | Health Technology |
Frantz Medical Ventures
 Frantz Medical Ventures Investment ManagersFinance Frantz Medical Ventures (Frantz Medical Ventures) is a venture capital subsidiary of Frantz Medical Group founded in 1979. The firm is headquartered in Mentor, Ohio. | Finance |
GlaxoSmithKline North Carolina
GlaxoSmithKline North Carolina Pharmaceuticals: OtherHealth Technology Part of GSK Plc, GlaxoSmithKline North Carolina is a private company that develops, manufactures, and markets vaccines and other pharmaceuticals. The company is based in Durham, NC. | Health Technology |
AstraZeneca, Inc.
 AstraZeneca, Inc. BiotechnologyHealth Technology Part of AstraZeneca PLC, AstraZeneca, Inc. manufactures vaccines. | Health Technology |
| The Boys & Girls Clubs of Philadelphia | |
UPMC Enterprises
UPMC Enterprises Investment ManagersFinance UPMC Enterprises (UPMC Enterprises) is a venture capital subsidiary of University of Pittsburgh Medical Center founded in 2014. The firm is headquartered in Pittsburgh, Pennsylvania. | Finance |
Century Therapeutics, Inc. /Old/
 Century Therapeutics, Inc. /Old/ BiotechnologyHealth Technology Century Therapeutics, Inc. operates as a biotechnology company. It develops transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with significant unmet medical need. The company has created a allogeneic cell therapy platform that includes induced pluripotent stem cells, or iPSCs, differentiation know-how to generate immune effector cells from iPSCs, or iPSC-derived cells, clustered regularly interspaced short palindromic repeats, or CRISPR, mediated precision gene editing that allows it to incorporate multiple transgenes and remove target genes intended to optimize cell product performance, sophisticated protein engineering capabilities to develop proprietary next generation chimeric antigen receptors, or CARs, its proprietary Allo-EvasionTM technology intended to prevent rejection of its cell products by the host immune system, and cutting edge manufacturing capabilities intended to minimize product development and supply risk. Century Therapeutics was founded on March 5th, 2018 and is headquartered by Philadelphia, PA. | Health Technology |
